|
|
|
|
|
Last Trade
|
Last Trade:
$5.53
|
Change:
0.06 (1.10%)
|
Trade Time:
May 26
|
Market Cap:
$806.50M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical stage immuno-oncology company pioneering the development of
genetically engineered allogeneic T cell product candidates for the treatment of
cancer. We are developing a pipeline of off-the-shelf T cell product candidates
that are designed to target and kill cancer cells. Our engineered T cells are
allogeneic, meaning they are derived from healthy donors for intended use in any
patient, rather than from an individual patient for that patient's use, as in
the case of autologous T cells. We believe this key difference will enable us to
deliver readily available treatments faster, more reliably, at greater scale,
and to more patients.
Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy,
has emerged as a revolutionary and potentially curative therapy for patients
with hematologic cancers, including refractory cancers.
|
|
|
|